All patients | HM after SLE | HM before/concurrent | ||||
---|---|---|---|---|---|---|
n | 45 | 29 | 16 | |||
Hodgkin's lymphoma | 5 | (11%) | 3 | (10%) | 2 | (13%) |
Indolent lymphoma | 9 | (20%) | 6 | (21%) | 3 | (19%) |
DLBCL | 15 | (33%) | 13 | (45%) | 2 | (13%) |
Burkitt's lymphoma | 1 | (2%) | 1 | (3%) | 0 | (0%) |
T cell lymphoma | 4 | (9%) | 1 | (3%) | 3 | (19%) |
Multiple myeloma | 2 | (4%) | 1 | (3%) | 1 | (6%) |
Leukaemia/MPD/MDS | 9 | (20%) | 4 | (14%) | 5 | (31%) |
DLBCL, diffuse large B cell lymphoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; SLE, systemic lupus erythematosus.